Literature DB >> 32147814

Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study.

M S M Persson1, K E Harman1, Y Vinogradova2, S M Langan3, J Hippisley-Cox4, K S Thomas1, S Gran1.   

Abstract

BACKGROUND: A rising incidence and high mortality were found for bullous pemphigoid (BP) over a decade ago in the UK. Updated estimates of its epidemiology are required to understand the healthcare needs of an ageing population.
OBJECTIVES: To determine the incidence, prevalence and mortality rates of BP in England from 1998 to 2017.
METHODS: We conducted a cohort study of longitudinal electronic health records using the Clinical Practice Research Datalink and linked Hospital Episode Statistics. Incidence was calculated per 100 000 person-years and annual point prevalence per 100 000 people. Multivariate analysis was used to determine incidence rate ratios by sociodemographic factors. Mortality was examined in an age-, sex- and practice-matched cohort, using linked Office of National Statistics death records. Hazard ratios (HRs) were stratified by matched set.
RESULTS: The incidence was 7·63 [95% confidence interval (CI) 7·35-7·93] per 100 000 person-years and rose with increasing age, particularly for elderly men. The annual increase in incidence was 0·9% (95% CI 0·2-1·7). The prevalence almost doubled over the observation period, reaching 47·99 (95% CI 43·09-53·46) per 100 000 people and 141·24 (95% CI 125·55-158·87) per 100 000 people over the age of 60 years. The risk of all-cause mortality was highest in the 2 years after diagnosis (HR 2·96; 95% CI 2·68-3·26) and remained raised thereafter (HR 1·54; 95% CI 1·36-1·74).
CONCLUSIONS: We report a modest increase in the incidence rate of BP, but show that the burden of disease in the elderly population is considerable. Mortality is high, particularly in the first 2 years after diagnosis.
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Entities:  

Mesh:

Year:  2020        PMID: 32147814     DOI: 10.1111/bjd.19022

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal:  Am J Clin Dermatol       Date:  2022-05-17       Impact factor: 6.233

2.  Autoantibodies Against the Immunodominant Bullous Pemphigoid Epitopes Are Rare in Patients With Dermatitis Herpetiformis and Coeliac Disease.

Authors:  Antti Nätynki; Jussi Tuusa; Kaisa Hervonen; Katri Kaukinen; Outi Lindgren; Laura Huilaja; Nina Kokkonen; Teea Salmi; Kaisa Tasanen
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

3.  Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England.

Authors:  M S M Persson; K E Harman; K S Thomas; J R Chalmers; Y Vinogradova; S M Langan; J Hippisley-Cox; S Gran
Journal:  BMC Med Res Methodol       Date:  2021-02-04       Impact factor: 4.615

4.  Improving Care in Eosinophil-Associated Diseases: A Charter.

Authors:  David J Jackson; Praveen Akuthota; Rebeca Andradas; Albert J Bredenoord; Amanda Cordell; Sarah Gray; Joyce Kullman; Sameer K Mathur; Ian Pavord; Florence Roufosse; Christian Rubio; Irena Clisson Rusek; Dagmar Simon; Mary Jo Strobel; Tonya Winders
Journal:  Adv Ther       Date:  2022-04-30       Impact factor: 4.070

5.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

Review 6.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

7.  The incidence of bullous pemphigoid continues to increase in England.

Authors:  C E Bax; V P Werth
Journal:  Br J Dermatol       Date:  2020-06-15       Impact factor: 9.302

Review 8.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

9.  Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.

Authors:  Zeyad Albadri; Kristofer Thorslund; Henrike Häbel; Oliver Seifert; Carina Grönhagen
Journal:  Acta Derm Venereol       Date:  2020-10-14       Impact factor: 3.875

10.  Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Authors:  Jia Chen; Xuming Mao; Wenling Zhao; Bingjie Zhang; Xinyi Chen; Chenyang Yu; Zehui Zheng; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.